The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus

Xiao, Lian Li; Wu, Yu; Qian, Jing; Tan, Yuan; Xie, Guo Liang; Zhang, Kang Jian; Wang, Yi Gang; Jia, Xiao Yuan; Liu, Xin‐Yuan

doi:10.4161/cbt.10.3.12308

Cited by 7 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we constructed a survivin-driven, chimeric 5/11 fiber-modified conditionally replicating adenovirus, CRAd5/11-Sp-eGFP. In previous studies, the exogenous gene expression cassettes usually were located in the E1 region or E3 region (22)(23)(24)(25)(26). In this study, the exogenous gene expression cassette was inserted into the region between E4 and the fiber by using a novel shuttle vector which contained the modified fiber and an expression cassette.…”

Section: Discussionmentioning

confidence: 99%

A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy

Mao

Wang

et al. 2012

International Journal of Oncology

View full text Add to dashboard Cite

Effective therapies are needed for malignant glioma patients because of the poor prognosis. Gene therapy combined with virotherapy could be the strategy of choice. In this study, we constructed a modified conditionally replicating adenoviral vector CRAd5/11-Sp-eGFP. The novel vector has the following features: i) the transduction efficiency of CRAd5 was increased using a chimeric fiber 5/11 consisting of an Ad5 tail and an Ad11 shaft and knob; ii) the tumor-specific replication of the vector was improved by utilizing the human survivin promoter to control E1 expression and a poly-A signal inserted right after the inverted terminal repeat (ITR) to stop the non-specific transcriptional activity of the ITR; iii) an expression cassette was inserted into the region between the fiber and E4 region for expressing eGFP. In vitro assays demonstrated that the novel vector could efficiently replicate and kill human glioma cells. Furthermore, CRAd5/11‑Sp-eGFP exhibited significantly increased antitumor effects compared with the control adenoviruses in a xenograft model of glioma. Our results indicate that CRAd5/11-Sp-eGFP represents a promising candidate drug in the treatment of malignant gliomas.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy

Mao

Wang

et al. 2012

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma

Cheng

Liu

et al. 2012

Mol Cell Biochem

View full text Add to dashboard Cite

Osteosarcoma (OS) severely threatens the health of young people and understanding on the molecular mechanisms of OS etiology enables gene therapy to become an effective therapeutic modality. However, insufficient expression level of genes using existing vectors limits the clinical application of gene therapy for OS. To solve the problem, we developed an oncolytic adenoviral vector, OAT, which can selectively and efficiently replicate in OS cells to enhance the expression of transferred genes. We demonstrated that OAT-mediated TRAIL expression is significantly elevated after infection of OS cells than replication-incompetent Ad5 vector. Increased antitumor capacity was observed in OS cells after OAT-TRAIL treatment both in vitro and in vivo. In normal cells, adenoviral replication, TRAIL expression and growth-inhibiting effect were quite limited when OAT-TRAIL was administrated, showing a high biosafety of this oncolytic adenoviral vector. Collectively, we generated an efficient and promising expression vector for OS gene therapy.

show abstract